* Investigators are listed in the Appendix section.
Abstract
Background. Peritonitis is a common complication of chronic peritoneal dialysis (CPD) and can be associated with technique failure. Enterococcus is an uncommon peritoneal pathogen in children receiving CPD but represents a potential therapeutic challenge due to its innate resistance to cephalosporins and emerging resistance to glycopeptides. Results. Among the 392 patients, 340 episodes of culture-positive peritonitis were evaluated. Twenty of these episodes were due to Enterococcus species (5.9%). There were no clinical characteristics uniquely associated with enterococcal peritonitis at presentation. After 3 days of therapy, 75% of patients were pain free, 95% had decreased effluent cloudiness and 90% were afebrile. Only one patient required a catheter exchange, and all patients experienced full functional recovery. Despite broad in vitro resistance to cephalosporins and 21% resistance to glycopeptides, neither in vitro resistance pattern nor choice of empiric antibiotic regimen affected short-or long-term outcomes.
Conclusions. Enterococci are likely responsible for ∼6% of

Introduction
Peritonitis is a common complication seen in patients receiving chronic peritoneal dialysis (PD) in the setting of end-stage renal disease (ESRD). Peritonitis remains the most common infection in both adults and children receiving PD as renal replacement therapy [1, 2] . Furthermore, it can be associated with technique failure, necessitating transition to haemodialysis. In fact, >40% of paediatric PD patients who change dialysis modality do so due to excessive infectious complications [3] .
Given the severity of the sequelae associated with peritonitis, guidelines for optimal management in patients receiving chronic PD have been established, both for empiric therapy and for treatment of specific organisms. The International Society for Peritoneal Dialysis (ISPD) has published treatment recommendations for children and adults in 2000 and 2005, respectively [1, 4] . More recently, the International Pediatric Peritonitis Registry (IPPR) published a prospective evaluation of the implementation of the 2000 ISPD opinion-based treatment guidelines for management of peritonitis in children receiving chronic PD [2] .
Enterococcus species are an infrequent cause of peritonitis in chronic PD patients but can present a potential therapeutic challenge. Enterococci are ubiquitous Gram stain-positive intestinal flora that share several important characteristics with enteric Gram stain-negative organisms. Of primary concern, enterococci are resistant to most cephalosporin antibiotics and, in recent years, have increasingly become resistant to glycopeptides [5, 6] . Furthermore, episodes of peritonitis due to enterococci tend to be severe and have been associated with recurrent peritonitis [1, 7] . The present study is based on data collected by the IPPR between 2001 and 2004 on 20 episodes of enterococcal peritonitis, representing the largest reported series of enterococcal peritonitis episodes in children to date. Our aim was to more fully characterize this uncommon form of peritonitis in children receiving chronic PD.
Materials and methods
The IPPR is a global consortium of 47 paediatric dialysis centres, comprised of 29 European, 2 Asian and 16 American centres. It was established in October 2001 in order to address validation of the ISPD paediatric peritonitis treatment guidelines and to evaluate the distribution of causative organisms and their respective resistance patterns (see Appendix section for the list of participating centres).
Data collection methods
The data collection methodology utilized by the IPPR has been described extensively elsewhere [8] . Briefly, data input was performed completely via an Internet-based web platform (http://www.peritonitis.org). Data pertaining to basic patient and PD modality characteristics, clinical presentation with peritonitis, microbiological results, empiric treatment and its subsequent modifications, clinical treatment response, and final outcomes were submitted prospectively during the course of the peritonitis episode. These results were automatically checked for both accuracy and consistency. Additionally, centre-specific demographic data and PD practices were collected by means of an online questionnaire. The IPPR protocol was approved by the ethical committee or institutional review board at all participating centres.
Definitions
Peritonitis. In accordance with the ISPD guidelines, peritonitis was diagnosed if the patient presented with (i) cloudy effluent, (ii) an effluent cell count of at least 100 cells/µL and (iii) at least 50% polymorphonuclear cells in the differential cell count. Peritonitis was considered to be relapsing if peritonitis with the same organism (defined by biochemical differentiation and resistance pattern or two consecutive culture-negative episodes) developed within 4 weeks of termination of antibiotic therapy.
Catheter exit-site appearance. The catheter exit-site appearance was characterized according to a standardized scoring system which was based on the presence and severity of swelling, crust, erythema, pain, and discharge [9] .
Treatment of peritonitis. Treatment of the peritonitis episodes was considered to be in accordance with the ISPD guidelines if (i) diagnostic criteria for peritonitis were fulfilled and/or an organism was grown on culture, (ii) the patient was assessed for the presence of the peritonitis risk factors defined by the ISPD guidelines and (iii) empiric treatment was initiated according to the recommendations of the guidelines [i.e. either a first-generation cephalosporin and ceftazidime, or a glycopeptide (vancomycin or teicoplanin) and ceftazidime]. Antibiotic therapy was intended to be modified based on the results of culture and sensitivity testing.
Disease severity score. The disease severity score (DSS), which ranged from 0 to 5, was calculated as the sum of points for pain (0-no pain; 1-moderate pain or nausea not requiring a specific therapy; 2-severe pain, usually requiring analgesic therapy, or vomiting; and 3-peritoneal pain with tense abdomen and/or paralytic bowel) and fever (0 indicates <37.5°C, 1 indicates 37.5-38.9°C and 2 indicates >38.9°C).
Treatment responses. Early treatment response was defined as the clinical response 72 h after initiation of treatment. The response was considered 'satisfactory' if the DSS was ≤2 at 72 h after beginning empiric treatment and the cloudiness of the effluent had decreased. Late treatment response was defined as the clinical outcome of the patients 4 weeks after treatment had begun. The final outcomes examined were death, the need for catheter exchange, technique failure, the occurrence of relapse and a composite end point 'full functional recovery'. Full functional recovery was defined as continuation of PD without functional impairment (i.e. loss of ultrafiltration or apparent formation of adhesions) regardless of whether or not relapse occurred or catheter replacement was required.
Statistical analyses
Potential differences between groups were assessed using ANOVA followed by Newman-Keuls testing for continuous variables and by chisquare analysis for categorical variables. The risk for an adverse outcome associated with parameters, such as patient characteristics, initial presentation, culture results and treatment modalities, was assessed by single and multiple logistic regression models. Differences between proportions or mean values and inclusion of variables in regression models were assumed to be significant at P < 0.05.
Results
Patients and peritonitis episodes
The IPPR enrolled 392 participants; each of whom experienced one or more episodes of peritonitis while receiving chronic PD. Participants were 54% male and ranged in age from 1 month to 22 years (median age 9.8 years). Mean dialysis duration at the time of initial registry entry was 1.7 ± 1.5 years (median 1.2 years; range 3 days-8.3 years). These 392 patients experienced 548 episodes of peritonitis, or 1.4 ± 0.8 episodes per patient (median 1; range 1-6). The 47 participating centres each contributed an average of 11.6 ± 10.4 (median 8.0; range 1-44) peritonitis episodes in 8.7 ± 7.1 (median 6; range 1-31) patients.
Of the 548 peritonitis episodes, 501 (91.4%) met the criteria for an episode treated according to the ISPD paediatric guidelines and were included in the analyses. Of these, 10 (2%) were fungal peritonitis episodes and have been excluded from all analyses presented here, if not stated explicitly otherwise. The remaining 491 episodes were comprised of 221 (45%) Gram-positive, 119 (24%) Gramnegative and 151 (31%) culture-negative episodes.
Enterococcal peritonitis episodes Patient characteristics. Comparative demographics and clinical data for the patients with enterococcal peritonitis, Staphylococcus aureus peritonitis, other Gram-positive organism peritonitis and Gram-negative peritonitis are listed in Table 1 . Enterococci were recovered from the effluent in 5.9% (20/340) of the culture-positive peritonitis episodes and 9.0% (20/221) of the episodes of peritonitis due to Gram-positive organisms. Nineteen of the twenty episodes (95%) were community acquired. The 20 patients with enterococcal peritonitis were 11.6 ± 5.4 years old (range 1.6-18.5) and had been receiving dialysis for 1.2 ± 0.9 years (range 0.1-3.5). These children, on average, had experienced 0.7 ± 1.0 prior episodes of peritonitis (range 0-3). All 20 patients had double-cuffed catheters; the majority (80%) of which were Tenckhoffs; 75% of the Tenckhoff catheters had curled intraperitoneal segments with straight (50%) or swan neck (44%) tunnels. Exit sites were predominantly directed downward (55%), although 25% of the patients were noted to have upward-facing exit sites. Automated peritoneal dialysis (APD) was the dialysis modality used by 18/20 patients (90%). Sixteen of the 20 patients (80%) used standard, lactate-based dialysate, 3 (15%) used bicarbonate-based dialysate and 1 (5%) used combined bicarbonate/lactate dialysate. None of the 20 patients who developed enterococcal peritonitis had a vesicostomy, an enterostomy or an ureterostomy. All 20 patients were receiving exit-site antibiotic prophylaxis at the time of enrolment.
Clinical presentation. Clinical information regarding initial presentation is provided in Table 2 . Patients with enterococcal peritonitis tended to present with both pain (95%) and cloudy peritoneal fluid (100%); 35% of patients experienced severe pain, and 75% had markedly cloudy fluid. Fever (temperature ≥38.0°C) was a common (45%), but not universal, presenting symptom. Mean cell count at presentation was 2433 ± 2916 (median 1300; range 1-9800). The percentage of polymorphonuclear leucocytes was 81% ± 18% (median 84; range 37-99%).
Mean DSS was 2.1 ± 1.0 (median 2.0; range 0-4); none of the patients had exit-site erythema, crusting, tenderness, swelling or discharge (exit-site score of 0 for all 20 patients).
Treatment and response to therapy. Clinical responses after 3 days of therapy are listed in Table 2 . Overall, patients with enterococcal peritonitis responded adequately to treatment as all 20 patients had a DSS ≤2 on Day 3; 70% had a DSS of 0. After 3 days of therapy, 75% of patients were pain free, 55% had clear effluent and 95% had decreased cloudiness compared with Day 0. On treatment Day 3, 90% of the patients were afebrile (temperature ≤38.0°C), which was comparable with patients with Gram-negative peritonitis and lower than patients with other Gram-positive organisms (P=0.03).
The in vitro antibiotic sensitivities for the 20 episodes of enterococcal peritonitis are listed in Table 3 . The antibiotics with the best sensitivity profiles against enterococci were imipenem (100% susceptible) and glycopeptides (79%). The antibiotics to which the enterococci were least susceptible were first-generation cephalosporins (5% susceptible), second-generation cephalosporins (10%) and third-generation cephalosporins (15%). The most effective combination of antibiotics was a glycopeptide and ceftazidime (86% sensitive). In comparison, the combination of a first-generation cephalosporin and ceftazidime achieved only 20% sensitivity (4/20) . Enterococcal isolates were sensitive to a glycopeptide combined with an aminoglycoside 75% of the time (6/8). When patients with an enterococcal isolate sensitive to the empiric therapy were compared with patients who had an enterococcal isolate resistant to the empiric therapy, there was no significant difference in Day 3 response to therapy.
Of the 20 episodes of enterococcal peritonitis, 45% (9/20) received empiric therapy with vancomycin and ceftazidime, and 55% (11/20) received empiric therapy with cefazolin and ceftazidime. When culture results became available, therapy was modified accordingly. In the glycopeptide group, five remained on vancomycin, two switched to ampicillin, one switched to ciprofloxacin and one switched to tobramycin. In the cephalosporin group, six remained on cefazolin, three switched to vancomycin and two switched to ampicillin. Despite the resistance patterns described above, when patients receiving empiric vancomycin/ceftazidime were compared with those receiving empiric cefazolin/ceftazidime, on treatment Day 3, there was no significant difference with regard to fever, abdominal pain or effluent cloudiness (P > 0.05 for all three parameters).
Outcomes following peritonitis and risk factors for relapse. Final outcomes for patients with enterococcal peritonitis, as well as comparative outcomes for patients with other Gram-positive and Gram-negative peritonitis, are listed in Table 4 . Although one patient required a PD catheter exchange, no patients in the enterococcal group needed to change renal replacement modality, and all patients had a full functional recovery. Fifteen percent of patients with enterococcal peritonitis experienced relapsing peritonitis; however, this was not significantly different from the rate seen with other pathogens. Neither the empiric antibiotic choice nor the enterococcal isolate resistance pattern influenced outcome following peritonitis. Since all patients with enterococcal peritonitis experienced a functional recovery and none of the episodes required transition to haemodialysis, it was not possible to identify risk factors for poor outcomes. However, the presence of >10 000 cells in the effluent sample on Day 0 (OR 3.9; 95% CI 1.1-14.3, P < 0.05) and dwell time prolongation compared with baseline, the practice of lengthening dwell time when converting to continuously cycling therapy to maintain daily ultrafiltration at a constant value (OR 5.6; 95% CI 1.4-22.6, P < 0.05), were associated with an increased risk for relapsing peritonitis. There was no association between the presence of fever, severe abdominal pain on Day 0 or marked cloudiness on Day 0, and relapse. Additionally, there was no significant association between relapse and the empiric use of a first-generation cephalosporin versus a glycopeptide.
Discussion
Initially designed specifically to test the opinion-based 2000 ISPD Pediatric Peritonitis Guidelines [4] , the IPPR has provided a unique opportunity to examine many aspects of peritonitis in children receiving chronic PD. The large, internationally derived data set encompassing >500 peritonitis episodes in >300 children includes detailed information on 20 episodes of peritonitis due to Enterococcus species, representing the largest reported series of such cases in children and providing an opportunity to better characterize infections due to this uncommon paediatric peritoneal pathogen.
When compared with peritonitis due to other organisms seen more commonly in the IPPR, there were few distinguishing characteristics at presentation among PD patients with enterococcal peritonitis. Patients tended to be older than those with Gram-negative peritonitis and tended to have fewer previous peritonitis episodes than patients with other Gram-positive peritonitis pathogens. There were no differences in catheter cuff number, tunnel anatomy, exit-site orientation, connection modality or dialysis modality compared with peritonitis due to the other pathogens. Of note, all 20 patients developed enterococcal peritonitis despite the use of prophylactic antibiotic therapy at the exit site and without evidence of exit-site infection at time of diagnosis.
Patients presented uniformly with pain and cloudy effluent, exhibiting high peritoneal cell counts. Fever was present in nearly half of the patients, and overall mean DSS at onset was 2.1, no different from the Registry as a whole. With the exception of the fact that Enterococcus was rarely recovered from the exit site, none of the patient characteristics at presentation differed significantly from those with infections due to other peritoneal pathogens. Thus, it is not possible to identify likely cases of enterococcal peritonitis at presentation, and clinicians must continue to rely on effluent cultures to make this diagnosis.
Our in vitro sensitivity testing of enterococcal isolates confirmed a broad resistance to cephalosporins. While third-generation cephalosporins performed better than firstand second-generation agents, only 15% of isolates were sensitive to them. Glycopeptides proved more efficacious; Each individual organism grown from the effluent was counted as one observation. Intermediate sensitivity was counted as resistant. however, 21% of isolates demonstrated glycopeptide resistance. The most effective antibiotic tested was imipenem, to which 100% of enterococci were susceptible. As expected, only 20% of enterococcal isolates showed in vitro sensitivity to the combination of a first-and thirdgeneration cephalosporin. The combination of a glycopeptide and ceftazidime was effective in vitro against 86% of isolates, and 75% were sensitive to an aminoglycoside/glycopeptide combination. These in vitro results suggest that the 2000 ISPD Guidelines recommending empiric therapy with a first-and third-generation cephalosporin combination should have been unsuccessful in cases of enterococcal peritonitis. However, to our surprise, this was not the case. Despite the high level in vitro resistance to cephalosporins and not insignificant resistance to glycopeptides among enterococci observed in this study, clinical response to empiric therapy was excellent regardless of the empiric antibiotic combination employed. By treatment Day 3, 75% of patients were pain free, 95% had diminished effluent cloudiness and 90% were afebrile. Moreover, patients receiving empiric therapy with cefazolin/ ceftazidime were just as likely to be afebrile, to be pain free and to have a clearing effluent by Day 3 as those receiving vancomycin/ceftazidime. Although the availability of culture results 72 h after onset allowed practitioners to modify antibiotic regimens accordingly, the initial clinical response in these 20 cases of enterococcal peritonitis was excellent and unrelated to in vitro sensitivity patterns. This is in stark contrast to previously reported IPPR data on Gram-negative peritonitis in which the pathogen's in vitro resistance pattern was shown to be closely associated with therapeutic response [10] . The reason for this dissociation between in vitro sensitivity and clinical response in our patients with enterococcal peritonitis is unclear. However, there is pharmacokinetic evidence that the serum and effluent concentrations of cefazolin and ceftazidime achieved with standard continuous intraperitoneal administration greatly exceed the known minimal inhibitory concentration (MIC) of susceptible organisms; in fact, the effluent concentrations have been shown to exceed, by 2-4-fold, the lower limit of MIC for resistant organisms [11, 12] . We speculate that the high intraperitoneal concentrations of the cephalosporins may have resulted in in vivo effectiveness not predicted by in vitro sensitivity patterns.
Consistent with the excellent observed initial clinical response to empiric therapy, these 20 children had generally superb outcomes. All 20 patients recovered from the infectious episode, and none of the 20 required transition to another renal replacement modality. Three patients (15%) had a relapse, but this was not significantly different from the rates seen with other organisms (8-14%). Moreover, the empiric use of cephalosporins without a glycopeptide was not associated with an increased incidence of relapsing peritonitis.
Limited data exist regarding enterococcal peritonitis in patients receiving chronic PD, even in adults. To the best of our knowledge, our report, which represents the largest cohort of such children, is the first to provide detailed data regarding signs and symptoms at presentation, initial response rates to empiric therapy, and organism-specific antibiotic susceptibility. The majority of published data represent case series detailing either the epidemiology of vancomycin-resistant enterococcal (VRE) peritonitis [13] [14] [15] or the clinical response of VRE to alternate antimicrobial agents such as linezolid, daptomycin and quinupristin/ dalfopristin [16] [17] [18] [19] . The largest of these highlighted the early poor outcomes experienced by patients with VRE peritonitis; five of nine patients expired, and two of the remaining four experienced PD technique failure [15] . Larger, single and multi-centre reports regarding peritonitis outcomes have also discussed enterococcal peritonitis [20] [21] [22] [23] . These studies have reported that the incidence of enterococcal peritonitis among chronic PD patients ranges from 1.9% to 4.1% [20] [21] [22] [23] , which is slightly lower than the incidence seen in our population (5.9%). Two studies reported good outcomes in patients with enterococcal peritonitis, with resolution rates and patient survival rates >90% [21, 22] . However, one study reported a non-significant trend towards higher rates of hospitalization and mortality in patients with enterococcal peritonitis [20] , and a second reported a high incidence of recurrent peritonitis in individuals with enterococcal infections [7] . More recently, a large study from Australia detailed 116 cases of enterococcal peritonitis in 103 adults receiving chronic PD [24] . Of the 116 cases, 52 were polymicrobial, and 64 had pure enterococcal growth from culture. Although multivariate analysis did not identify any predictive factors in patients with enterococcal peritonitis, univariate analysis highlighted advanced age and the presence of coronary heart disease as risk factors [24] . Our results are in accordance with these findings as paediatric patients with enterococcal peritonitis did not have any distinguishing characteristics at presentation. One-half of the 116 patients in the Australian study received an initial empiric antibiotic regimen of vancomycin and gentamicin, and another third received empiric therapy with cefazolin and gentamicin or a third-generation cephalosporin [24] . No data regarding susceptibilities is available; however, the antibiotic regimen was modified in 59% of the pure enterococcal events; ∼80% of the changes consisted of cessation of gentamicin/cephalosporin therapy and conversion to vancomycin. Although outcomes in patients with polymicrobial enterococcal peritonitis were poor, patients with pure enterococcal peritonitis had outcomes no different than those with non-enterococcal disease. Our study is consistent with this finding, suggesting that children with enterococcal peritonitis are likely to have excellent short-and long-term outcomes regardless of the empiric regimen chosen.
In summary, analysis of these IPPR data suggests that enterococci will be responsible for ∼6% of culture-positive peritonitis episodes in children receiving PD in the setting of ESRD. Although the isolates demonstrated a broad resistance to cephalosporins, both alone and in combination, 3-day response rates to empiric therapy with cephalosporins and long-term outcomes were excellent. While an empiric regimen including a glycopeptide would seem to be ideal if enterococcal peritonitis is suspected, implementation will necessarily be limited to rare situations in which enterococcal peritonitis recurrence is a concern, as there is no characteristic presentation typical of enterococcal infection. Fortunately, patients who initially received a cephalosporin-based empiric regimen until culture results are available are likely to respond quickly and have full functional recovery. Finally, glycopeptide resistance among enterococci is a growing concern (21% resistance in the present study), and continued empiric use is likely to increase resistance; as the absence of a glycopeptide in the initial empiric regimen did not adversely affect outcomes, empiric use of these antimicrobial agents should be made after careful consideration.
